Medical cannabis and pregnancy — why the answer is no, and what alternatives exist

THC crosses the placenta and reaches the fetus. Concentrations in fetal tissues are typically lower than maternal but measurable. THC is also detectable in breast milk for hours to days after maternal use. Both routes deliver cannabinoid exposure to a developing nervous system.

Observational cohort studies have associated maternal cannabis use with: lower birth weight, possible attention and behavioural differences in childhood, possible association with preterm birth. The studies have substantial limitations (recall bias, polysubstance use, socioeconomic confounders) — they are not high-quality evidence of harm. But "we do not have high-quality evidence of harm" is not the same as "we have evidence of safety". For a developing nervous system over 9 months, the precautionary position is to defer.

CBD has fewer studied effects but also fewer studied safety outcomes in pregnancy. The current scientific position is the same: insufficient safety data, deferral pending more data.

Patients with chronic pain, severe anxiety, or refractory insomnia who were stable on cannabinoid therapy before pregnancy understandably worry about discontinuing. The Docto24 doctor will work with you to taper safely and to find pregnancy-safe alternatives — not because cannabinoid therapy is unequivocally harmful, but because cannabinoid therapy in pregnancy is not adequately studied and the conventional alternatives have safety profiles that are.

The exception sometimes raised is hyperemesis gravidarum (severe pregnancy-related nausea). Even there, current obstetric guidance prefers ondansetron, doxylamine-pyridoxine, or other established anti-emetics over cannabinoid therapy. The case for cannabinoid use in pregnancy hyperemesis is genuinely thin and is not the typical Section 21 framework.

**Chronic pain** — paracetamol remains pregnancy-compatible at standard doses. Physiotherapy, structured movement programmes, and cognitive-behavioural pain-management approaches are all appropriate. NSAIDs are restricted, particularly in the third trimester.

**Insomnia** — sleep hygiene and CBT-I are first-line and entirely pregnancy-compatible. Diphenhydramine and doxylamine have established pregnancy use; benzodiazepines are generally avoided.

**Anxiety** — psychotherapy is the foundation. Some SSRIs (sertraline notably) have substantial pregnancy data and continued use during pregnancy is often appropriate; the doctor or psychiatrist managing your anxiety care will discuss the specific risk-benefit.

**Nausea** — pregnancy-specific anti-emetic ladders exist and should be the framework, not cannabinoid adjunct.

Once pregnancy and breastfeeding conclude, the cannabinoid pathway becomes available again on the same Section 21 framework. Patients who deferred during pregnancy can re-enter the assessment process post-partum or post-weaning, and the doctor will reassess the indication, current treatment, and whether cannabinoid therapy is appropriate at that point. Pregnancy is a defined period of deferral, not a permanent disqualification.